Search results for "Metabolic diseases"

showing 10 items of 753 documents

Regulated Proteolysis of RAGE and AβPP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease

2009

Epidemiological studies have linked type 2 diabetes mellitus (T2DM) with an increased risk of developing Alzheimer's disease (AD). In T2DM, the elevated blood glucose level promotes formation of advanced glycation end products (AGEs). The receptor for AGEs (RAGE) is a type I membrane-protein and is also able to import amyloid-beta (Abeta) from the blood across the blood-brain-barrier into the brain. Oligomeric Abeta peptides disturb synaptic function in the brain and are believed to contribute to the development of AD. Abeta peptides are released from the amyloid-beta protein precursor (AbetaPP) after sequential proteolysis by beta- and gamma-secretases but alpha-secretase-mediated cleavage…

medicine.medical_specialtyendocrine system diseasesProteolysisReceptor for Advanced Glycation End ProductsAmyloid beta-Protein PrecursorAlzheimer DiseaseGlycationInternal medicinemental disordersmedicineAnimalsHumansReceptors ImmunologicProtein precursorProtein kinase AReceptorAmyloid beta-Peptidesmedicine.diagnostic_testChemistryGeneral Neurosciencenutritional and metabolic diseasesGeneral MedicinePsychiatry and Mental healthClinical PsychologyCholesterolEndocrinologyDiabetes Mellitus Type 2EctodomainPeptide transportAmyloid Precursor Protein SecretasesGeriatrics and GerontologySignal transductionJournal of Alzheimer's Disease
researchProduct

Interaction of Diet/Lifestyle Intervention and TCF7L2 Genotype on Glycemic Control and Adiposity among Overweight or Obese Adults: Big Data from Seve…

2021

Objective . The strongest locus which associated with type 2 diabetes (T2D) by the common variant rs7903146 is the transcription factor 7-like 2 gene ( TCF7L2 ). We aimed to quantify the interaction of diet/lifestyle interventions and the genetic effect of TCF7L2 rs7903146 on glycemic traits, body weight, or waist circumference in overweight or obese adults in several randomized controlled trials (RCTs). Methods . From October 2016 to May 2018, a large collaborative analysis was performed by pooling individual-participant data from 7 RCTs. These RCTs reported changes in glycemic control and adiposity of the variant rs7903146 after dietary/lifestyle-related interventions in overweight or ob…

medicine.medical_specialtyendocrine system diseasesbusiness.industryComputer applications to medicine. Medical informaticsR858-859.7nutritional and metabolic diseasesOverweightlaw.inventionRandomized controlled triallawInternal medicineGenotypeLifestyle interventionMedicinemedicine.symptombusinessTCF7L2GlycemicHealth Data Science
researchProduct

Treatment of patients with essential hypertension and microalbuminuria.

1998

There has been increasing interest in the question of whether microalbuminuria can be used in the risk stratification of patients with essential hypertension. A cluster of cardiovascular and/or renal risk factors may be associated with microalbuminuria in hypertension. Despite this, prospective data about the potential role of microalbuminuria as a prognostic marker of cardiovascular and/or renal risk have been sparse and inconclusive until now. Blood pressure values have been considered the most important determinant of microalbuminuria in essential hypertension; however, hyperinsulinaemia--a metabolic component-was noted to be present in conjunction with high blood pressure. Furthermore, …

medicine.medical_specialtyendocrine system diseasesbusiness.industrynutritional and metabolic diseasesProspective dataurologic and male genital diseasesmedicine.diseaseDisease clusterEssential hypertensionfemale genital diseases and pregnancy complicationsSurgeryPharmacotherapyFelodipineInternal medicineRisk stratificationHypertensionmedicineDoxazosinAlbuminuriaHumansPharmacology (medical)MicroalbuminuriabusinessAntihypertensive Agentsmedicine.drugDrugs
researchProduct

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.

2019

In general, both European and American clinical guidelines have addressed the management of atherogenic dyslipidaemia in an unconvincing and even superficial way, largely because of the available therapeutic limitations. Consequently, this type of dyslipidaemia is underdiagnosed, under-treated, and under-controlled. Given the recent presentation of the 2019 guidelines of the European Atherosclerosis Society and the European Society of Cardiology on the management of dyslipidaemias, it seems appropriate to examine its position with respect to atherogenic dyslipidaemia and/or its main components, the increase in triglyceride-rich lipoproteins, and the decrease of high-density lipoprotein chol…

medicine.medical_specialtyendocrine system diseaseschemistry.chemical_compoundTriglycerides/HDL CholesterolInternal medicineMedicineHumanscardiovascular diseasesTriglyceridesGeneral Environmental ScienceLipoprotein cholesterolDyslipidemiasbusiness.industryCholesterolCholesterol HDLGeneral Engineeringnutritional and metabolic diseasesAtherosclerosisEuropechemistryPractice Guidelines as TopicCardiologyEuropean atherosclerosis societyGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)businessClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome

2014

Resistin is an adipocyte- and monocyte-derived cytokine which has been implicated in the modulation of insulin action, energy, glucose and lipid homeostasis. Resistin has been associated with insulin resistance and many of its known complications. As a molecular link between metabolic signals, inflammation, and vascular dysfunction, resistin can be proposed as playing a significant role in the heightened inflammatory state induced by metabolic stress linked to excessive caloric intake, thus contributing to the risk for metabolic syndrome (MetS), type 2 diabetes (T2DM), and cardiovascular diseases (CVD). In this review, we highlighted the role of resistin, as an inflammatory cytokine, in the…

medicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInflammationType 2 diabetesModels BiologicalType 2 diabetemetabolic syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceAdipocyteInternal medicineDiabetes mellitusDrug DiscoverymedicineHumansResistin030304 developmental biologyMetabolic SyndromePharmacology0303 health sciencesbusiness.industryDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Insulinnutritional and metabolic diseasesCardiovascular diseasemedicine.disease3. Good healthcardiovascular diseasesEndocrinologyDiabetes Mellitus Type 2chemistryCardiovascular Diseases030220 oncology & carcinogenesisImmunologyResistintype 2 diabetesInflammation MediatorsMetabolic syndromemedicine.symptombusinesshormones hormone substitutes and hormone antagonists
researchProduct

Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population

2021

Background: This study sought to investigate the prevalence and clinical outcome of left ventricular (LV) geometry in prediabetes and type 2 diabetes mellitus (T2DM) and the impact of glucose metabolism on the incidence of left ventricular hypertrophy (LVH). Methods: 15,010 subjects (35–74 years) of the population-based Gutenberg Health Study were categorized into euglycemia, prediabetes, and T2DM according to clinical and metabolic (HbA1c) information. Clinical outcome was assessed via structured follow-up. Results: The study comprised 12,121 individuals with euglycemia (81.6%), 1415 with prediabetes (9.5%), and 1316 with T2DM (8.9%). Prevalence of LVH increased from euglycemia (10.2%) ove…

medicine.medical_specialtyendocrine system diseasestype 2 diabetes mellitusPopulationprediabetesCarbohydrate metabolismleft ventricular concentric remodelingLeft ventricular hypertrophyArticleInternal medicineMedicineMass indexPrediabetescardiovascular diseaseseducationeducation.field_of_studybusiness.industryIncidence (epidemiology)Hazard ratioRType 2 Diabetes Mellitusnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseleft ventricular hypertrophyleft ventricular geometryCardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct

Pharmacotherapy for gestational diabetes

2018

Introduction: Gestational diabetes mellitus (GDM) represents impaired carbohydrate metabolism during pregnancy and is characterized by progressive insulin resistance and compensatory hyperinsulinaemia. If inadequately treated, it may lead to fetal macrosomia and other adverse outcomes. Areas covered: In this review, the authors summarize the current evidence from studies on the use of insulin and other agents for the treatment of women with GDM. Expert opinion: Lifestyle management is of paramount importance for the treatment of GDM. In pharmacotherapy, insulin remains the long-established mainstay of treatment. NPH (Neutral Protamine Hagedorn) and soluble human insulin have long been estab…

medicine.medical_specialtyinsulinlifestyleendocrine system diseasesmedicine.medical_treatment030209 endocrinology & metabolismCarbohydrate metabolism03 medical and health sciences0302 clinical medicineInsulin resistancePharmacotherapyPregnancyInternal medicineHumansMedicineHypoglycemic AgentsPharmacology (medical)030212 general & internal medicineDipeptidyl-Peptidase IV InhibitorsPharmacologyDipeptidyl-Peptidase IV InhibitorsPregnancytherapybusiness.industryInsulinnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseincretinPregnancy ComplicationPregnancy ComplicationsGestational diabetesDiabetes GestationalEndocrinologyGestational diabeteDipeptidyl-Peptidase IV InhibitorFemalebusiness
researchProduct

The role of fibrate treatment in dyslipidemia: an overview.

2012

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributin…

medicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorAdipokineFibratechemistry.chemical_compoundInternal medicineDrug DiscoverymedicineAnimalsHumansTriglyceridesDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationTriglycerideCholesterolbusiness.industryFibric Acidsnutritional and metabolic diseasesLipid metabolismCholesterol LDLmedicine.diseaseFibrates dyslipidemia cardiovascular risk diabetes.EndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent pharmaceutical design
researchProduct

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion

2021

Introduction Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a first-line treatment but can be poorly tolerated because of its side effects, and therapeutic failure is possible. Somatostatin analogues have limited efficacy because of their poor affinity to somatostatin (SST) receptors. Pasireotide is a somatostatin analogue with a much higher affinity to SST receptors, especially SST5, and it could thus be more efficient for treating nesidioblastosis-related hypo…

medicine.medical_specialtymedicine.medical_treatmentNesidioblastosisOctreotideCase ReportHypoglycemiaGastroenterologychemistry.chemical_compoundInternal medicinemedicineDiazoxidePharmacology (medical)business.industryInsulinnutritional and metabolic diseasesmedicine.diseasenesidioblastosisPasireotidediazoxideSomatostatinhypoglycemiachemistrySitagliptinpasireotide LARbusinessmedicine.drugClinical Pharmacology : Advances and Applications
researchProduct

Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix meta…

2018

Context: The correlation between aggressive prostate cancer and obesity mainly based on body mass index (BMI) and pathology after surgery remains controversial. Aims: The aim of the study was to correlate BMI, visceral adiposity index (VAI), and the plasmatic levels of leptin, adiponectin, and matrix metalloproteinase-3 (MMP-3), and biomarkers of adipose tissue function, with the detection of Gleason patterns 4 and 5 at biopsy. Subjects and Methods: Consecutive patients with prostate cancer at 12-core transrectal biopsy were enrolled. BMI, waist circumference (WC), blood samples to evaluate the plasmatic levels of triglycerides (TG) and high-density lipoproteins (HDL), adiponectin, leptin, …

medicine.medical_specialtyobesityProstate biopsyUrology030232 urology & nephrologyAdipose tissuebody mass indexlcsh:RC870-923GastroenterologyleptinGleason patternmatrix metalloproteinase-303 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineBiopsymedicineAdiponectinmedicine.diagnostic_testbusiness.industryLeptinnutritional and metabolic diseaseslcsh:Diseases of the genitourinary system. Urologymedicine.diseaseprostate cancervisceral adiposity indexTransrectal biopsy030220 oncology & carcinogenesisOriginal ArticleAdiponectinbusinessBody mass index
researchProduct